The results obtained from the phase I/II study of SEL24/MEN1703 in AML showed a good safety profile and efficacy in relapsed or refractory AML as a single agent, suggesting that this first-in-class dual PIM/FLT3 kinase inhibitor could be a promising new strategy to treat AML patients particularly those with IDH mutations [177,178]. Here, PIM1 is linked to acute myeloid leukemia.